Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.53 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.42 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.42 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.41 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.41 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.41 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7016468 | 0.88 | MEN1 (0.74) | MEN1KMT2APOLBALDH1A1HPGD | |
| SCHEMBL7015349 | 0.85 | MEN1 (0.55) | MEN1KMT2ATAS1R3TAS1R1POLB | |
| SCHEMBL7014523 | 0.83 | MEN1 (0.55) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL7020854 | 0.80 | MEN1 (0.60) | MEN1KMT2APOLBALDH1A1HPGD | |
| SCHEMBL13781698 | 0.80 | MEN1 (0.59) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL7013155 | 0.79 | LMNA (0.53) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL7018581 | 0.79 | NPC1 (0.73) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL13491660 | 0.79 | MEN1 (0.46) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL13784450 | 0.79 | MEN1 (0.50) | MEN1KMT2APOLBNPC1RAB9A | |
| SCHEMBL7014019 | 0.77 | TSHR (0.59) | MEN1KMT2ATAS1R3TAS1R1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002537396-A | — | — | 2002-11-05 | — | — | JP | claimed |
| US-20020099072-A1 | [1,8] naphthyridine derivatives having antiviral activity | BIOCHEM PHARMA INC. | 2002-07-25 | — | — | US | claimed |
| US-6340690-B1 | INHIBITING HEPATITIS OR HERPES VIRAL INFECTIONS | BIO-CHEM PHARMA INC. (CA) | 2002-01-22 | — | — | US | claimed |
| EP-1155017-A1 | [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | Shire Biochem Inc. (CA) | 2001-11-21 | — | — | EP | claimed |
| WO-2000050424-A1 | [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | BIOCHEM PHARMA INC. (CA) | 2000-08-31 | — | — | WO | claimed |
| US-6605614-B2 | Anti-hepatitis or anti-herpes | BIOCHEM PHARMA INC. (CA) | 2003-08-12 | — | — | US | disclosed |
| EP-1155017-B1 | [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | SHIRE BIOCHEM INC (CA) | 2003-01-15 | — | — | EP | disclosed |
| US-20020099072-A1 | [1,8] naphthyridine derivatives having antiviral activity | BIOCHEM PHARMA INC. | 2002-07-25 | — | — | US | disclosed |
| US-6340690-B1 | INHIBITING HEPATITIS OR HERPES VIRAL INFECTIONS | BIO-CHEM PHARMA INC. (CA) | 2002-01-22 | — | — | US | disclosed |
| EP-1155017-A1 | [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | Shire Biochem Inc. (CA) | 2001-11-21 | — | — | EP | disclosed |
| WO-2000050424-A1 | [1,8] NAPHTHYRIDINE DERIVATIVES HAVING ANTIVIRAL ACTIVITY | BIOCHEM PHARMA INC. (CA) | 2000-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099072-A1 | [1,8] naphthyridine derivatives having antiviral activity | HAVCR2, MAVS, NTPCR | MEN1 4721/4885KMT2A 4352/4885TAS1R3 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.